Boston Scientific Corp. on Thursday won approval from the U.S. Federal Trade Commission for its $27 billion acquisition of Guidant Corp., on condition that the company bring a new competitor to the market by selling all assets related to Guidant’s vascular business to Abbott Laboratories.

Anticipating FTC concerns about concentration in the vascular market, Boston Scientific proposed the sale to Abbott as part of its definitive buyout offer to Guidant shareholders in January.